India has launched a nationwide Human Papillomavirus (HPV) vaccination campaign to prevent cervical cancer in adolescent girls, a move welcomed by the World Health Organisation’s South‑East Asia office as a pivotal step toward the region’s elimination goals.
WHO underscores regional momentum
Dr Catharina Boehme, Officer-in-Charge, WHO South-East Asia, said on X, “This landmark step, led at the highest level of government, reflects India’s strong commitment to protecting adolescent girls from cervical cancer”.
“India’s introduction of HPV vaccination at a national scale will have a far-reaching impact – accelerating progress not only for the country, but for the Region and the world. Despite being preventable, cervical cancer continues to claim the life of a woman every two minutes globally, and the WHO South-East Asia Region bears nearly one-quarter of the global burden. With today’s milestone, nine of the ten countries in the Region now include HPV vaccination in their national immunisation programmes – a powerful testament to growing regional momentum toward eliminating cervical cancer as a public health problem,” she said.
“WHO remains committed to support Member States achieve high and equitable coverage of vaccination, and to strengthen screening and treatment services in line with the global 90-70-90 targets for 2030 – vaccinating 90% of girls by age 15, screening 70% of women by ages 35 and 45, and ensuring 90% of women with pre-cancer and invasive cancer receive appropriate treatment,” she said.
Prime Minister announces national rollout
Earlier in the day, the Prime Minister signalled the campaign’s launch at a public event in Ajmer, Rajasthan, framing it as a flagship investment in women’s health within India’s wider public-health and social protection agenda.
In an X post, PM Modi said, “We are leaving no stone unturned to ensure that the daughters of the country are healthy and prosperous. In this direction, this morning, around 11:30 AM, I will launch the nationwide HPV vaccination campaign in Ajmer, Rajasthan. The objective of this initiative is the prevention of cervical cancer. During this time, I will also have the opportunity to lay the foundation stones and inaugurate several projects, along with handing over appointment letters to my young colleagues.”
Scale of the programme and who is covered
- Target cohort: approximately 1.15 crore (11.5 million) girls aged 14 years each year across all States and Union Territories, making it one of the largest single‑age HPV cohorts globally.
- Cost to families: free of charge at designated government health facilities, under the government‑funded Universal Immunization Programme.
- Programme aim: build high, equitable coverage in line with the global 90-70-90 targets for elimination as a public health problem.
Why this policy move matters for women’s health
The nationwide rollout is being framed by health officials as both a technical and a social intervention: an evidence‑based cancer prevention tool that also signals a shift toward earlier, life‑course-based investments in women’s health.
- Cervical cancer is caused by persistent infection with high‑risk HPV types; vaccination before exposure substantially reduces future disease risk.
- HPV vaccination, when paired with organised screening and timely treatment, is the cornerstone of elimination strategies endorsed by WHO.
- National rollouts reduce geographic and income‑based disparities by making preventive tools available at the population level, rather than relying on out‑of‑pocket uptake in urban or private settings.
Governance framework and how the campaign is anchored in India’s health system
The campaign is being implemented through India’s Universal Immunization Programme under the Ministry of Health and Family Welfare, with financing and policy guidance routed through the National Health Mission and aligned with India’s National Health Policy. Operational guidelines are expected to draw on the Ministry of Health and Family Welfare’s immunisation and AEFI protocols, creating a common regulatory and programmatic framework for states and Union Territories.
| Component | Planned/expected approach | System interface |
|---|---|---|
| Target population | Girls aged 14 years, with annual cohorts sustained nationwide | Universal Immunization Programme platforms |
| Delivery settings | School-based sessions where feasible; outreach and fixed-site sessions at public health facilities | Coordination between health and education departments at state/district levels |
| Access and cost | Free-of-cost vaccination at designated government facilities | Central procurement and state implementation |
| Cold chain and logistics | Utilisation of the national vaccine cold-chain network | Electronic Vaccine Intelligence Network (eVIN) for stock and temperature monitoring |
| Workforce | Auxiliary nurse midwives, staff nurses, vaccinators; community mobilisation through frontline workers | School Health and Wellness Programme support for in‑school outreach |
| Safety monitoring | Standard Adverse Events Following Immunization (AEFI) surveillance with rapid investigation and causality assessment | AEFI committees at national, state, and district levels; lot release and quality control through national laboratories |
| Data and monitoring | Session-wise recording and coverage tracking; supportive supervision and micro‑planning | State dashboards and routine programme reviews |
| Screening linkage | Progressive scale‑up of cervical screening for women at recommended ages | Integration with noncommunicable disease programmes and women’s health services |
Equity and reach: closing the gaps
Officials acknowledge that the success of the campaign will hinge on its ability to reach girls who are least connected to formal health and education systems. States are being asked to integrate HPV delivery into existing micro‑plans for routine immunisation while tailoring outreach to local vulnerabilities.
- Out‑of‑school adolescents: special outreach sessions through community platforms to avoid missed cohorts.
- Remote and underserved areas: mobile teams and periodic intensification to extend coverage beyond district headquarters.
- Urban poor settlements: coordination with municipal health services to reach migrant and transient populations.
- Informed participation: multilingual information materials and engagement with parents, teachers, religious and local leaders to support uptake and address concerns.
Health outcomes and system impacts to track
For policy-makers, the campaign doubles as a test of India’s ability to deliver a new adolescent vaccine at scale while maintaining public confidence. Central and state authorities are expected to follow a small set of indicators that reflect both health impact and system performance.
- Coverage: proportion of the target cohort receiving HPV vaccine by state and district, including urban-rural and socioeconomic differentials.
- Safety: AEFI reporting rates, investigation timeliness, and transparent public reporting.
- Screening access: availability of age‑appropriate screening and timely treatment pathways in public facilities.
- Burden indicators: long‑term trends in HPV prevalence and cervical cancer incidence via population‑based cancer registries.
- Programme efficiency: vaccine wastage rates, cold‑chain performance, and session completion rates.
Timelines and alignment with elimination goals
The government has signalled that it views HPV vaccination as a long‑term system commitment, not a one‑off drive, with timelines explicitly linked to WHO’s elimination thresholds.
- Immediate: establish regular session plans across schools and health facilities; ensure uninterrupted supply and cold‑chain readiness.
- Near term: sustain annual vaccination of new 14‑year‑old cohorts and reinforce catch‑up strategies where needed.
- By 2030: align national coverage, screening, and treatment performance with elimination benchmarks embedded in the 90‑70‑90 framework.
Regional significance beyond India
India’s scale and public‑sector delivery footprint position the campaign to influence market stability, training standards, and operational good practices across South‑East Asia. Vaccine procurement at national level can shape price and supply dynamics, while India’s experience in school‑based delivery, digital stock management and AEFI communication is likely to feed into regional technical guidance. The emphasis on high and equitable coverage, coupled with strengthened screening and treatment, reflects an elimination pathway now embraced by most countries in the region.
What the official rollout notes
Government messaging has linked the HPV campaign to a broader narrative of women’s empowerment and preventive care, underlining that protection against cervical cancer is being treated as a basic public service rather than a discretionary expense.
- The nationwide effort marks a decisive step in women’s health under the “Swastha Nari” vision, centring prevention, protection and equity.
- The programme’s intent is to provide consistent access at government health facilities for each new cohort of 14‑year‑old girls across all States and Union Territories, embedding HPV vaccination as a routine, rights‑based component of adolescent health services.
